Sergio Bracarda

27.1k total citations · 5 hit papers
236 papers, 11.6k citations indexed

About

Sergio Bracarda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Sergio Bracarda has authored 236 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Pulmonary and Respiratory Medicine, 101 papers in Oncology and 73 papers in Cancer Research. Recurrent topics in Sergio Bracarda's work include Renal cell carcinoma treatment (109 papers), Prostate Cancer Treatment and Research (62 papers) and Cancer Genomics and Diagnostics (61 papers). Sergio Bracarda is often cited by papers focused on Renal cell carcinoma treatment (109 papers), Prostate Cancer Treatment and Research (62 papers) and Cancer Genomics and Diagnostics (61 papers). Sergio Bracarda collaborates with scholars based in Italy, United States and France. Sergio Bracarda's co-authors include Bernard Escudier, Alain Ravaud, Camillo Porta, Stéphane Oudard, Robert J. Motzer, Thomas E. Hutson, Viktor Grünwald, Robert A. Figlin, John A. Thompson and Norbert Hollaender and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sergio Bracarda

221 papers receiving 11.3k citations

Hit Papers

Efficacy of everolimus in... 2007 2026 2013 2019 2008 2007 2017 2010 2010 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
  2. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
  3. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    2017 1.2k citations Margitta Retz, Andrea Necchi et al. profile →
  4. Phase 3 trial of everolimus for metastatic renal cell carcinoma
    2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
  5. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
    2010 632 citations Bernard Escudier, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sergio Bracarda 7.6k 5.8k 4.4k 3.8k 2.1k 236 11.6k
Frédéric Rolland 6.7k 0.9× 4.8k 0.8× 4.3k 1.0× 3.0k 0.8× 2.7k 1.3× 142 11.6k
Gary R. Hudes 6.8k 0.9× 6.1k 1.1× 3.5k 0.8× 3.6k 0.9× 1.2k 0.6× 102 10.7k
Charles M. Baum 8.2k 1.1× 5.9k 1.0× 4.7k 1.1× 3.4k 0.9× 1.4k 0.7× 71 12.8k
Christian Kollmannsberger 8.7k 1.1× 5.5k 1.0× 4.8k 1.1× 3.4k 0.9× 4.2k 2.0× 387 14.0k
Viktor Grünwald 6.8k 0.9× 5.5k 1.0× 4.1k 0.9× 3.0k 0.8× 1.1k 0.5× 328 10.4k
Tim Eisen 7.0k 0.9× 7.4k 1.3× 4.4k 1.0× 4.1k 1.1× 875 0.4× 145 12.8k
Christine Chevreau 10.2k 1.3× 6.3k 1.1× 6.2k 1.4× 3.8k 1.0× 2.7k 1.3× 310 15.6k
Laurence Albigès 10.7k 1.4× 6.5k 1.1× 5.1k 1.2× 4.2k 1.1× 2.1k 1.0× 460 14.4k
I. Bodrogi 6.4k 0.8× 4.3k 0.7× 3.6k 0.8× 2.9k 0.8× 2.4k 1.2× 78 10.3k
Manuela Schmidinger 5.4k 0.7× 3.9k 0.7× 3.0k 0.7× 2.3k 0.6× 1.1k 0.5× 180 8.5k

Countries citing papers authored by Sergio Bracarda

Since Specialization
Citations

This map shows the geographic impact of Sergio Bracarda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Bracarda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Bracarda more than expected).

Fields of papers citing papers by Sergio Bracarda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio Bracarda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Bracarda. The network helps show where Sergio Bracarda may publish in the future.

Co-authorship network of co-authors of Sergio Bracarda

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Bracarda. A scholar is included among the top collaborators of Sergio Bracarda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Bracarda. Sergio Bracarda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Borghesi, Simona, Nicolò Borsellino, Anna Caliò, et al.. (2025). Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies. BMC Cancer. 25(1). 127–127. 1 indexed citations
2.
Campione, Marina, Sara Elena Rebuzzi, Lucia Fratino, et al.. (2025). Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy. Technology in Cancer Research & Treatment. 24. 2244058514–2244058514. 1 indexed citations
3.
Iacovelli, Roberto, Emanuela Fantinel, Davide Bimbatti, et al.. (2024). Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study.. Journal of Clinical Oncology. 42(4_suppl). TPS495–TPS495.
4.
Antonuzzo, Lorenzo, Rosa Tambaro, Sebastiano Buti, et al.. (2024). READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma. SHILAP Revista de lepidopterología. 5. 100068–100068. 4 indexed citations
5.
Bauckneht, Matteo, Chiara Ciccarese, Riccardo Laudicella, et al.. (2024). Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives. Cancer Treatment Reviews. 124. 102698–102698. 11 indexed citations
6.
Matsubara, Nobuaki, Johann S. de Bono, Christopher Sweeney, et al.. (2023). Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(2). 230–237.e1. 5 indexed citations
7.
Desiderio, Jacopo, Andrea Sagnotta, Irene Terrenato, et al.. (2021). Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. Scientific Reports. 11(1). 7150–7150. 21 indexed citations
8.
9.
Santoni, Matteo, Francesco Piva, Camillo Porta, et al.. (2020). Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer. 19(2). e84–e91. 20 indexed citations
10.
Antonelli, Alessandro, Marianna Noale, Angelo Porreca, et al.. (2019). Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study). Urologia Internationalis. 103(1). 8–18. 16 indexed citations
11.
Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772. 121 indexed citations
12.
Bono, Johann S. de, Ugo De Giorgi, Daniel Nava Rodrigues, et al.. (2018). Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research. 25(3). 928–936. 227 indexed citations
13.
Porreca, Angelo, Marianna Noale, Walter Artibani, et al.. (2018). Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health and Quality of Life Outcomes. 16(1). 122–122. 22 indexed citations
14.
Gacci, Mauro, Marianna Noale, Walter Artibani, et al.. (2017). Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus. 3(4-5). 321–324. 12 indexed citations
15.
Lorenzo, Giuseppe Di, Sergio Bracarda, Donatello Gasparro, et al.. (2016). Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine. 95(2). e2299–e2299. 12 indexed citations
16.
Bellmunt, Joaquim, Arjun Vasant Balar, Matthew D. Galsky, et al.. (2016). IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology. 27. vi270–vi270. 10 indexed citations
17.
Massari, Francesco, Alessandra Modena, Chiara Ciccarese, et al.. (2015). Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. Critical Reviews in Oncology/Hematology. 98. 254–263.
18.
Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 372(9637). 449–456. 2339 indexed citations breakdown →
19.
Escudier, Bernard, A Płużańska, P. Koralewski, et al.. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet. 370(9605). 2103–2111. 1722 indexed citations breakdown →
20.
Favero, A. Del, Enzo Ballatori, Maurizio Tonato, et al.. (1993). Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. Journal of Clinical Oncology. 11(12). 2396–2404. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frédéric Rolland Breakdown of academic impact, for papers by Gary R. Hudes Breakdown of academic impact, for papers by Charles M. Baum Breakdown of academic impact, for papers by Christian Kollmannsberger Breakdown of academic impact, for papers by Viktor Grünwald Breakdown of academic impact, for papers by Tim Eisen Breakdown of academic impact, for papers by Christine Chevreau Breakdown of academic impact, for papers by Laurence Albigès Breakdown of academic impact, for papers by I. Bodrogi Breakdown of academic impact, for papers by Manuela Schmidinger
Rankless by CCL
2026